Sitemap > Breaking Research > GenitoUrinary Tract Disorders
Displaying 201 - 250 of 759 results
- Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
- Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
- Prostaglandin receptors are mediators of vascular function in endometrial pathologies.
- Participation of endogenous endothelin and ET(A) receptor in premicturition contractions in rats with bladder outlet obstruction.
- Leflunomide--an immunomodulator--induces regression of endometrial explants in a rat model of endometriosis.
- Design and synthesis of selective alpha1B adrenoceptor antagonists.
- A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy.
- Endothelin-A-receptor antagonist LU 302146 inhibits electrostimulation-induced bladder contractions in vivo.
- Contractile mechanisms coupled to TRPA1 receptor activation in rat urinary bladder.
- Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study.
- Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
- Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.
- Prevalence and risk factors for urinary incontinence in women with type 2 diabetes and impaired fasting glucose: findings from the National Health and Nutrition Examination Survey (NHANES) 2001-2002.
- Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development.
- Downregulation of angiogenic factors and their downstream target molecules affects the deterioration of erectile function in a rat model of hypercholesterolemia.
- Economic evaluation of duloxetine for the treatment of women with stress urinary incontinence: a Markov model comparing pharmacotherapy with pelvic floor muscle training.
- Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.
- A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.
- Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing.
- Evaluation of the Efficacy and Safety of Once-a-Day Dosing of Tadalafil 5mg and 10mg in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
- Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial.
- Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial.
- IkappaB kinase 2 inhibition corrects defective nitrergic erectile mechanisms in diabetic mouse corpus cavernosum.
- New progesterone receptor antagonists: phosphorus-containing 11beta-aryl-substituted steroids.
- Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study.
- Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate.
- Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
- "Ejaculatory disorders and alpha1-adrenoceptor antagonists therapy: clinical and experimental researches".
- Role of estrogens in inflammatory response: expression of estrogen receptors in peritoneal fluid macrophages from endometriosis.
- Gabapentin treatment of neurogenic overactive bladder.
- The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size.
- Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?
- Prevalence of erectile dysfunction in Asian populations: a meta-analysis.
- The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States.
- Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension.
- Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35.
- The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking.
- Alterations of M(2)-muscarinic receptor protein and mRNA expression in the urothelium and muscle layer of the streptozotocin-induced diabetic rat urinary bladder.
- Diagnosis and management of endometriosis.
- Effect of regular phosphodiesterase type 5 inhibition in hypertension.
- The Sexual Arousal and Desire Inventory (SADI): a multidimensional scale to assess subjective sexual arousal and desire.
- Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction.
- Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors.
- Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: A landmark national US survey.
- Cardiovascular risk factors determine erectile and arterial function response to sildenafil.
- Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
- Efficacy of sildenafil citrate in treatment of erectile dysfunction: impact of associated premature ejaculation and low desire.
- An open-label, fixed-dose study of bupropion effect on sexual function scores in women treated for breast cancer.
- Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
- Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.